Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Trial details
- Registry ID
- NCT03737110
- Phase
- Phase 3
The FDA approved Rilonacept (Arcalyst® for Cryopyrin-Associated Periodic Syndromes (CAPS)) on 27 Feb 2008.
Drug identity checked against registry records
Also recorded as Arcalyst® for Cryopyrin-Associated Periodic Syndromes (CAPS); KPL-914
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent PericarditisNCT03737110 | Kiniksa Pharmaceuticals (UK), Ltd. | Phase 3 | Completed | 2020-05-29Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2008-02-27Day | Rilonacept | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125249", "applicant_as_listed_by_fda": "KINIKSA PHARMACEUTICALS (UK), LTD.", "brand_names": ["ARCALYST"], "active_ingredients": ["RILONACEPT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20080227", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |